272 related articles for article (PubMed ID: 35596182)
1. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values.
Amin S; Joo S; Nolte S; Yoo HK; Patel N; Byrnes HF; Costa-Cabral S; Johnson CD
BMC Cancer; 2022 May; 22(1):563. PubMed ID: 35596182
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
3. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population.
Pilz MJ; Loth FLC; Nolte S; Thurner AMM; Gamper EM; Anota A; Liegl G; Giesinger JM;
J Patient Rep Outcomes; 2024 May; 8(1):48. PubMed ID: 38695992
[TBL] [Abstract][Full Text] [Related]
4. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.
Vachon H; Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Fortpied C; Flechtner HH; Vestmoe Maraldo M; Hutchings M; Meijnders P; Aleman B; Lugtenburg P; Spina M; André M; Hertzberg M; Briones J; Bottomley A;
Eur J Haematol; 2021 May; 106(5):697-707. PubMed ID: 33570765
[TBL] [Abstract][Full Text] [Related]
5. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.
Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Pogoda K; Velikova G; Bjelic-Radisic V; Cardoso F; Brain E; Ignatiadis M; Piccart M; Van Tienhoven G; Mansel R; Wildiers H; Bottomley A;
Eur J Cancer; 2020 Jan; 125():69-82. PubMed ID: 31838407
[TBL] [Abstract][Full Text] [Related]
6. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
[TBL] [Abstract][Full Text] [Related]
7. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
Gough N; Koffman J; Ross JR; Riley J; Judson I
PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
[TBL] [Abstract][Full Text] [Related]
8. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
9. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
de Ligt KM; Aaronson NK; Liegl G; Nolte S;
Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
[TBL] [Abstract][Full Text] [Related]
10. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
12. EORTC QLQ-C30 general population normative data for the United States.
Rogge AA; Liegl G; Snyder C; Rose M; Nolte S;
Eur J Cancer; 2024 May; 202():114030. PubMed ID: 38552543
[TBL] [Abstract][Full Text] [Related]
13. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Laquente B; Macarulla T; Bugés C; Martín M; García C; Pericay C; Merino S; Visa L; Martín T; Pedraza M; Carnero B; Guardeño R; Verdaguer H; Mut A; Vilanova D; García A
BMC Palliat Care; 2020 Jul; 19(1):103. PubMed ID: 32650765
[TBL] [Abstract][Full Text] [Related]
14. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires.
Ficko SL; Pejsa V; Zadnik V
Radiol Oncol; 2019 Sep; 53(3):337-347. PubMed ID: 31553711
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Symeonides S; Hajek J; Ferguson T; Chang YH; Lee JL; Haas N; Sawrycki P; Sarwar N; Gross-Goupil M; Thiery-Vuillemin A; Mahave M; Kimura G; Perini RF; Saretsky TL; Bhattacharya R; Xu L; Powles T
Oncologist; 2024 Feb; 29(2):142-150. PubMed ID: 37589219
[TBL] [Abstract][Full Text] [Related]
19. Normative data for the EORTC QLQ-C30 from the Austrian general population.
Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
